ISRCTN13127656进行中（未招募）未知
A multi-centred, open label, randomised study assessing the cardiovascular outcomes following treatment of white coat hypertension with established anti-hypertensive drugs versus standard of care in the very elderly - feasibility study
niversity of Sussex0 个研究点目标入组 100 人开始时间: 2018年7月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients =75 years of age
- •2. Clinic sitting systolic BP =150 mmHg but <200 mmHg and diastolic BP <110 mmHg
- •3. Established diagnosis of white coat hypertension - confirmed if the mean ambulatory day time average systolic BP is <135 mmHg and diastolic BP is <85 mmHg (from at least 14 measurements) or for HBPM from BP readings twice a day for at least 5 days (ideally 7 days) at baseline
- •4. Not taken antihypertensive drug therapy within the last 6 months
- •5. Capacity to consent
- •6. Provision of documented informed consent
- •7. Ability to comply with the protocol and additional study visits and assessments
排除标准
- •1. Contraindication to the use of indapamide MR and perindopril in accordance with the summary of product characteristics
- •2. Regular non-steroidal anti-inflammatory drug (NSAID) use. Regular use being defined by the local GP with consideration to cardiovascular risk and blood pressure
- •3. Hypertensive emergency
- •4. Secondary hypertension
- •5. Postural hypotension (postural drop in systolic BP> = 20 mmHg or postural symptoms at screening)
- •6. Any stroke or myocardial infarction in the previous 6 months
- •7. Heart failure requiring treatment with drugs having an antihypertensive effect
- •8. Previous documented evidence of gout
- •9. eGFR less than 30ml/min
- •10. Montreal cognitive assessment score (MoCA) < 22
- •11. Life expectancy < 1 year due to malignancy or chronic disease
研究者
相似试验
终止
4 期
Facial Lipoatrophy TrialHIV Facial LipoatrophyInflammatory and Immune System - Rheumatoid arthritisACTRN12605000132640The University of New South Wales100
进行中（未招募）
1 期
HYVET-2: Treatment of white coat HYypertension in the Very Elderly Trial (HYVET 2) - Feasibility of a randomised controlled trialWhite Coat HypertensionEUCTR2017-004004-22-GBniversity of Sussex100
进行中（未招募）
1 期
Immunomonitoring by virus-specific T cells and evaluation as a prognostic marker for virus-induced diseases after kidney transplantatioAfter solid organ transplantation immunosuppressive treatment disrupts the individual balance between virus-replication and cellular immune response. This can lead to an elevated risk of severe viral complications.1) Immunosuppressive therapy might better be steered by measuring of virus-specific T cells than by blood levels of immunosuppressants solely.2) The antiviral treatment should be restricted to patients with high risk of viral diseases (high costs, severe side effects).MedDRA version: 19.1Level: PTClassification code 10052279Term: Renal and liver transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2009-012436-32-DEMedizinische Hochschule Hannover64
进行中（未招募）
1 期
Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age - LCS Pearl Index StudyContraceptionMedDRA version: 9.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2007-000420-40-FRBayer Schering Pharma Oy
进行中（未招募）
不适用
Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age - LCS Pearl Index StudyEUCTR2007-000420-40-FIBayer Schering Pharma Oy2,820